Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex
January 10 2019 - 12:00PM
Business Wire
Following successful beta program, the Simoa
SP-X next generation benchtop and CorPlex are launching ahead of
schedule to further revolutionize cancer research, immunotherapy
monitoring, and drug development
Quanterix Corporation (NASDAQ:QTRX), a company digitizing
biomarker analysis with the goal of advancing the science of
precision health, today announced the much-anticipated full launch
of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa
CorPlex Cytokine Panel, and broad menu of additional multiplex
panels. The new instrument platform and highly validated CorPlex
assays promise to revolutionize oncology research and drug
development. The progress made since the early access program was
initiated in early November 2018 with select industry leaders has
validated the performance and promise of the technology, resulting
in an accelerated timeline for full launch. The company is now
taking orders for shipping by April 1.
For the first time, researchers are able to access over one
thousand assay configurations of critical immunomodulatory
biomarkers for oncology research with multiplexing up to 10-plex
without sacrificing sensitivity. The broad assay menu covers more
than 50 analytes and enables researchers to easily develop custom
homebrew assays, further extending the range of applications to
include PK/PD and immunogenicity assays as well. Simoa CorPlex
assays undergo extensive validation, providing one of the most
highly validated assay menus in the industry, ensuring customers
can utilize the assays in the most demanding clinical and
translational research applications. The next generation Simoa
planar array technology utilized in CorPlex assays promotes
non-invasive biomarker measurements, supporting easier and more
approachable methods for determining drug efficacy and toxicity.
This addresses the previously unmet needs of oncology researchers,
particularly in the rapidly expanding fields of immuno-oncology and
immunotherapy, including checkpoint inhibitors and CAR-T cell
therapies.
“Immuno-oncology-based treatments have long shown tremendous
promise for improving how we treat cancers, but researchers have
lacked reliable methods to test the efficacy and toxicity of those
treatments early in therapeutic intervention,” said Kevin
Hrusovsky, Chief Executive Officer, President and Chairman of
Quanterix. “The ability to monitor the interaction of the patient
immune system and tumor biology by measuring multiple analytes
simultaneously is critical but has not been possible with
sufficient sensitivity until now. The SP-X instrument with CorPlex
assays mark the latest addition to our ultra-sensitive product
portfolio, supplying researchers with the tools they need to
determine whether immunotherapies are having the desired effect at
the earliest stages of the disease, saving resources and,
ultimately, lives.”
While immunotherapies have gained traction as a promising way to
treat many cancers, the inability to optimize dosing and the
occurrence of immune-related adverse events have hindered progress.
Critical biomarkers that would enable researchers to make informed
decisions with respect to dosing and toxicities are often at such
low concentrations that the reliable measurement has been
problematic until now. With Simoa CorPlex assays, researchers can
measure concentrations of key circulating cytokines and
immunological biomarkers across all stages of disease progression
including normal healthy baseline levels. This means that
researchers will be able to more quickly see whether the
immunotherapy or other cancer treatments are working, or
potentially avoid severe side effects such as neurotoxicity and
cytokine release syndrome. This means the Simoa CorPlex could have
the potential to catalyze dramatic reductions in treatments costs,
which can amount to several hundred thousand dollars a year.
General availability of Simoa CorPlex is made possible by the
SP-X Imaging and Detection System, Quanterix’ new state-of-the-art
benchtop imager that utilizes a proprietary planar array
technology, offering advanced multiplexing capabilities with the
same Simoa sensitivity found in the company’s HD-1 and SR-X
instruments. Building on the success of Quanterix’ flagship Simoa
technology, the SP-X and Simoa CorPlex are meeting the needs of
oncology researchers with the goal of revolutionizing patient
care.
About QuanterixQuanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of
precision health. The company’s digital health solution, Simoa, has
the potential to change the way in which healthcare is provided
today by giving researchers the ability to closely examine the
continuum from health to disease. Quanterix’ technology is designed
to enable much earlier disease detection, better prognoses and
enhanced treatment methods to improve the quality of life and
longevity of the population for generations to come. The technology
is currently being used for research applications in several
therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in
2007 and is located in Lexington, Massachusetts. For additional
Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release include statements
relating to the promise of the SP-X and Simoa CorPlex to
revolutionize oncology research and drug development and are based
on Quanterix’ expectations and assumptions as of the date of
this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may
cause Quanterix’ actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are discussed in Quanterix’ filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors"
sections contained therein. Except as required by
law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190110005527/en/
Lindsay PoolePAN
Communications617-502-4300quanterix@pancomm.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024